Method of enhancing glucose levels in the central nervous system
Presented herein are compositions and uses thereof for: (i) increasing or regulating glucose concentration in a central nervous system of a subject, (ii) inhibiting or delaying cognitive decline in a subject, (iii) enhancing cognitive function in a subject, and/or (iv) treating a disease or condition associated with a decreased level of glucose in a central nervous system of a subject. In some embodiments, the compositions provided herein comprise L-serine, or a precursor, derivative or conjugate thereof.
1 . A method for the treatment of Mild Cognitive Impairment (MCI) in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of L-serine, or a salt, a precursor, derivative or conjugate thereof;
wherein the subject is not diagnosed with and/or does not have Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex (ALS/PDC), dementia, Parkinson's Disease (PD), Huntington's disease (HD), Progressive Supranuclear Palsy (PSP), and/or Lewy Body Dementia (LBD); and
wherein prior to the administering, the concentration of glucose in the central nervous system or cerebrospinal fluid (CSF) of the subject is less than 45 mg/dL, and after the administration the concentration of glucose in the central nervous system or CSF is (i) increased by at least 20 percent or (ii) increased to an amount of at least 55 mg/dL.
2 . The method of claim 1 , wherein memory or learning ability is enhanced in the subject compared to an amount of memory or learning ability prior to administration of the L-serine or a salt, a precursor, derivative or conjugate thereof.
3 . The method of claim 1 , wherein the method comprises regulating or increasing glucose levels in the central nervous system of the subject.
4 . The method of claim 1 , wherein the subject is not diabetic.
5 . The method of claim 1 , wherein the subject is human.
6 . The method of claim 1 , wherein the subject is a post-menopausal woman or a woman over the age of 60.
7 . The method of claim 1 , wherein the subject is between the ages of 1 year and 21 years, or under the age of 50.
8 . The method of claim 1 , wherein the composition consists essentially of L-serine or free L-serine.
9 . The method of claim 1 , wherein the therapeutically effective amount comprises 5 grams to 100 grams of L-serine or a salt, a precursor, derivative or conjugate thereof.
10 . The method of claim 1 , wherein the administering comprises administering a dose of about 5 g/day to about 100 g/day of L-serine or a salt, a precursor, derivative or conjugate thereof.
11 . The method of claim 1 , wherein the composition does not contain an energy metabolism precursor.
12 . The method of claim 1 , comprising administering the composition daily, 1 to 8 times per day, for a duration of 2 to 24 weeks.
13 . The method of claim 1 , wherein the therapeutically effective amount of L-serine or a salt, a precursor, derivative or conjugate thereof is administered at a dose of about 25 mg/kg to 1,000 mg/kg body weight per day.
14 . The method of claim 1 , wherein the composition is administered orally in a dosage form selected from the group consisting of a chewable dosage form, a beverage formulation, a tablet, a capsule, a soft gel, a gel cap, and a liquid.
15 . The method of claim 1 , wherein the composition comprises free L-serine having a purity of at least 95%.